Integral analysis of the patient’s will be possible through collaboration of IDIBELL researchers and Anaxomics.
Systems biology is the computational and mathematical modelling of complex biological systems, which allows its analysis. It permits obtaining complex conclusions and new hypothesis from biological and biomedical research. It also enables the integration in a single analysis of all the information of patients, including both clinical data (clinical profile, received treatments, results of routine marker analysis) and “omics” data obtained in proteomics, genomics and metabolomics studies. Systems biology can be thus applied to any step of biomedical research, from basic research with cell cultures to clinical trials, used to optimize outcome measures or selection criteria, or even to clinical performance.
In fact, the integrative analysis of a patient through systems biology techniques is already being applied in world renowned hospitals, such as Memorial Sloan-Kettering Cancer Center or Mount-Sinai in New York, where it forms part of a protocol of treatment assignment for patients with certain cancers.
As omics techniques provide huge amounts of information and their cost per patient is constantly decreasing, many times they become indispensable for research projects. However, doctors and researchers often face the problem of dealing with these amounts of information for each patient, usually coming from unconnected experiments, and the difficulty of jointly interpret their results. The integration and interpretation of this information require very specific tools and knowledge. Systems biology aims to contribute to a better and more wide understanding of what is happening and why.
According to the Anaxomics’ CEO, Dr. José Manuel Mas, the variations of the mechanism of action in the same drug administered to different patients could determine its efficiency and toxicity. Currently there are “tools to map what happens in each patient and Anaxomics makes them available to doctors and researchers”.
The Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) and Anaxomics Biotech have signed an agreement to provide the use of systems biology techniques powered by Anaxomics to the IDIBELL research groups. The application of this innovative technology to IDIBELL researchers’ results can increase the value of their research and conclusions, no matter whether they are basic investigators or clinicians.
This agreement broadens the IDIBELL portfolio of services since it provides the researchers with the most advanced computational tools to extract the most from their results. Anaxomics offers personalized consulting services to identify molecular mechanisms associated with a disease or a drug by integrating clinical and molecular biology databases. Anaxomics is currently working with some top 20 national and international pharmas, and is already collaborating with important researches from Barcelona and the rest of the country.